Fisetin vs Navitoclax
Written by Aaron CuhaReviewed Sep 2026
The short answer
The senolytic anyone can buy, against the senolytic nobody should take. The ways they work overlap on the BCL-2 family of proteins, which is also why navitoclax destroys platelets. Fisetin's own lifespan claim failed to repeat in the program built to test such claims.
- Fisetin people
- 0
- Fisetin nulls
- 0
- Navitoclax people
- 137
- Navitoclax nulls
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 137 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
FisetinFisetin (senolytic flavonoid)
A plant compound found in strawberries, sold to clear worn-out cells. No results in people yet. One mouse study found longer life, and a bigger mouse program built to check it found none.
Column B
NavitoclaxNavitoclax (ABT-263), oral BCL-2, BCL-xL and BCL-w inhibitor
The most-quoted drug for clearing worn-out cells in mice, and the one you cannot give to healthy people. In its first study in people, 29 of 55 cancer patients saw their platelets, the blood cells that stop bleeding, drop to dangerous levels. Platelets stay alive using the same protein the drug blocks.
Side by side, on the facts we can check
| What we compare | Fisetin | Navitoclax |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Sold as a supplement; being tested in people for aging | Not approved for any use, in any country. It has been tested as a cancer drug since 2006. No study for ageing or for clearing worn-out cells is registered on ClinicalTrials.gov. |
| Half-life | ~1-3 hours | Not reported |
| Molecular weight | 286.2 Da | Not reported |
| How it works | It pushes worn-out cells to die off. That cuts the swelling signals those cells give off. | Shown in human cells and in mice: navitoclax sits in a pocket on BCL-2, BCL-xL and BCL-w. That frees up other proteins that tell the cell to die, so cells that lean on those three proteins die off. In mice, worn-out cells lean on them, which is why the drug hits those cells hardest. In people, platelets lean on the same protein, so their count drops. The cancer studies confirmed that. The clean-up effect seen in mice has never been shown in a person. |
| Studies in people | 1 | 4 |
| Evidence | Limited: 1 completed trial, none stating how many people | Moderate: 2 completed trials, 137 people given it |
| Legal status, US | Sold as a dietary supplement | Investigational, not approved |
Frequently asked questions
What is the difference between Fisetin and Navitoclax?
Fisetin: A plant compound found in strawberries, sold to clear worn-out cells. No results in people yet. One mouse study found longer life, and a bigger mouse program built to check it found none. Navitoclax: The most-quoted drug for clearing worn-out cells in mice, and the one you cannot give to healthy people. In its first study in people, 29 of 55 cancer patients saw their platelets, the blood cells that stop bleeding, drop to dangerous levels. Platelets stay alive using the same protein the drug blocks.
Which has stronger research evidence, Fisetin or Navitoclax?
Each compound gets a band worked out from facts we counted, with the math shown. Fisetin is Limited (1 completed trial, none stating how many people). Navitoclax is Moderate (2 completed trials, 137 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Fisetin and Navitoclax FDA-approved?
Fisetin: Sold as a supplement; being tested in people for aging. Navitoclax: Not approved for any use, in any country. It has been tested as a cancer drug since 2006. No study for ageing or for clearing worn-out cells is registered on ClinicalTrials.gov..
Related posts
Blog articles that cover Fisetin or Navitoclax, newest first.
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 27, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 27, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.